NCT01805895

A Pilot Study of Minocycline in Intracerebral Hemorrhage Patients

Minocycline in Acute Cerebral Hemorrhage (MACH) Trial

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Augusta University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The MACH Trial is a pilot study of 400mg minocycline over five days in acute intracerebral hemorrhage patients. The study will evaluation the safety and efficacy of minocycline in intracerebral hemorrhage patients.

Detailed description

MACH is a randomized trial of minocycline in intracerebral hemorrhage. 24 total subjects will be randomly assigned to minocycline or control (1:1). The first dose will be given intravenously. Subsequent doses will be given orally every 24 hours for a total of five doses. The study will test to see if the medication is safe in intracerebral hemorrhage. The pharmacokinetics of minocycline in intracerebral hemorrhage will be determined and the impact of minocycline on blood biomarkers.

Conditions

• Intracerebral Hemorrhage

Interventions

Type	Name	Description
DRUG	Minocycline	This arm will receive a total of 5 doses of minocycline. Dose 1 will be 400mg IV within 12-hours of onset of symptoms. Dose 2 will be 400mg oral, given daily on days 2-5 . Each dose is 24 hours apart.

Timeline

• Start date: 2013-02-01
• Primary completion: 2016-12-01
• Completion: 2016-12-01
• First posted: 2013-03-06
• Last updated: 2018-04-26
• Results posted: 2018-04-26

Locations

1 site across 1 country: United States